Clovis Oncology’s Rubraca now available via the Cancer Drugs Fund for ovarian, peritoneal, fallopian tube cancer

October 11, 2019
Medical Communications, Sales and Marketing Cancer, Clovis Oncology, NHS, NICE, Rubraca, fallopian tube cancer, ovarian cancer, peritoneal cancer, pharma

NICE has announced it has made an about-face on its earlier ruling for Clovis Oncology’s Rubraca (rucaparib), revealing that the …

neurolign

Neurolign secures eye diagnostic tech from Neuro Kinetics

October 11, 2019
Medical Communications

Neurolign Technologies has acquired US-based eye diagnostic technology firm Neuro Kinetics for an undisclosed sum. Neuro Kinetics is based in …

Bayer UK unveils new Artificial Intelligence ‘LifeHub’

October 10, 2019
Research and Development

Bayer has launched LifeHub UK as part of a network of global innovation hubs designed to accelerate and optimise disease …

NICE recommends pentosan polysulfate sodium for NHS treatment of bladder pain syndrome

October 10, 2019
Sales and Marketing NHS, NICE, bladder pain syndrome, pentosan polysulfate sodium

NICE has chosen to recommend pentosan polysulfate sodium, it has emerged, for use on the NHS in the treatment of …

novo_flag

Novo Nordisk enters into haemophilia gene therapy collaboration

October 10, 2019
Research and Development

Novo Nordisk and bluebird bio have announced they have entered into a three-year research collaboration to jointly develop next-generation in …

novartis_side_building

Novartis’ Cosentyx provides sustained resolution of psoriatic arthritis symptoms up to 2 years, data shows

October 10, 2019
Research and Development Cosentyx, Novartis, pharma, psoriatic arthritis

Novartis has unveiled new findings for Cosentyx (secukinumab) which show that the therapy generated “rapid and sustained resolution” of signs …

20120905_ucb_02

UCB Pharma to acquire Ra Pharmaceuticals in deal valued at $2.1bn

October 10, 2019
Sales and Marketing

UCB has agreed to acquire US-based Ra Pharmaceuticals for $2.1 billion in a deal that will enable the Belgian drug …

lung_ambition_alliance

The Lung Ambition Alliance: Stronger together

October 9, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Lung Ambition Alliance, lung cancer, pharma

Following our piece by AstraZeneca’s Patrick Connor introducing the Lung Ambition Alliance, a new cross-functional collaboration which aims to double …

FDA approves Pfenex’s osteoarthritis drug for patients at high risk of fracture

October 9, 2019
Research and Development, Sales and Marketing FDA, Pfenex, osteoporosis, pharma

The FDA has awarded US approval to Pfenex’s drug PF708, it has emerged, as a treatment for osteoporosis in certain …

gsk_l_rgb

GSK partners with Lyell Immunopharma to develop cell therapies for cancer

October 9, 2019
Research and Development

GlaxoSmithKline and Lyell Immunopharma have announced a five-year agreement to jointly develop new technologies to improve cell therapies for the …

novartis_window

Novartis’ ligelizumab outperforms Roche’s Xolair in chronic urticaria clearance

October 9, 2019
Research and Development Novartis, legelizumab, pharma, urticaria

Novartis has pulled back the curtain on new Phase 2b data for its IgE/FceR1 pathway-blocking drug ligelizumab, showing that the …

jj_sign_on_wall

Johnson & Johnson ordered to pay man $8bn over breast growth

October 9, 2019
Research and Development

US pharma giant Johnson & Johnson has been ordered to pay $8 billion in punitive damages to a man over …

FDA approves Clinuvel’s Scenesse for rare genetic disorder

October 9, 2019
Research and Development

The US FDA has approved Clinuvel’s Scenesse (afamelanotide 16mg) as the first ever treatment for a rare genetic metabolic disorder …

gilead-sciences

Gilead’s CAR-T therapy Yescarta now available via NHS Scotland for two forms of B-cell lymphoma

October 8, 2019
Manufacturing and Production, Sales and Marketing CAR T, CAR-T, NHS, Scotland, Scottish Medicines Consortium, pharma

News has broken that the Scottish Medicines Consortium (SMC) has chosen to approve the use of Gilead’s chimeric antigen receptor …

merckincweb2

4D Pharma to collaborate with MSD in vaccine development

October 8, 2019
Manufacturing and Production

4D pharma, a leader in the development of live biotherapeutics, has announced it has entered into a research collaboration to …

national_multiple_sclerosis_society_move_it_

Multiple Sclerosis Society launches fundraising appeal to raise £100m

October 8, 2019
Manufacturing and Production

The MS Society has launched a hard-hitting public appeal to raise £100m to stop multiple sclerosis. The Stop MS Appeal …

novartis_outside_1

FDA approves Novartis’ Beovu injection for wet age-related macular degeneration

October 8, 2019
Manufacturing and Production, Sales and Marketing Beovu, Eylea, FDA, Novartis, Regeneron, pharma

Novartis has secured FDA approval for its Beovu (brolucizumab) injection in the treatment of wet age-related macular degeneration (AMD), it …

Pfizer to develop Akcea/Ionis’ Antisense Drug for up to $1.5bn

October 8, 2019
Manufacturing and Production

Pfizer and Akcea Therapeutics have entered into an exclusive worldwide licensing agreement for Akcea’s phase 2 cardiovascular and metabolic candidate …

Johnson & Johnson win FDA Breakthrough status for cancer drug Zejula

October 7, 2019
Sales and Marketing

The US FDA has granted breakthrough therapy designation for Johnson & Johnson’s Zejula (niraparib) for the treatment of metastic prostate …

merdad_parsey

Gilead appoints Merdad Parsey as Chief Medical Officer

October 7, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Gilead Sciences have announced that Merdad Parsey will join the company as Chief Medical Officer, effective November 1st. Dr Parsey …

The Gateway to Local Adoption Series

Latest content